NASDAQ:AVBP ArriVent BioPharma Q3 2026 Earnings Results & Report $13.72 -0.44 (-3.11%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. ArriVent BioPharma beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.81 versus the -$1.0458 consensus estimate, while revenue of $5 million topped the $800 thousand estimate by $4.20 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call4:00 PM ET ArriVent BioPharma EPS ResultsActual EPS-$0.81Consensus EPS -$1.0458Beat/MissBeat by +$0.2358One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersArriVent BioPharma Revenue ResultsActual Revenue$5 millionExpected Revenue$800 thousandBeat/MissBeat by +$4.20 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ArriVent BioPharma Q3 2026 Earnings FAQ Did ArriVent BioPharma beat earnings estimates for Q3 2026? ArriVent BioPharma (NASDAQ:AVBP) reported earnings of -$0.81 per share for Q3 2026, beating the consensus estimate of -$1.0458. The report was announced on Monday, November 9, 2026. What was ArriVent BioPharma's revenue for Q3 2026? ArriVent BioPharma reported revenue of $5 million for Q3 2026, against a consensus estimate of $800 thousand. ArriVent BioPharma Earnings HeadlinesArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment ContinuesNovember 10 at 7:31 AM | rttnews.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Now Rated "Moderate Buy" by Wall Street AnalystsNovember 10 at 2:15 AM | americanbankingnews.comWhy Iran May Only Be the First MoveTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.November 10 at 1:00 AM | Behind the Markets (Ad)ArriVent BioPharma Reports Third Quarter 2026 Financial ResultsNovember 9 at 8:29 PM | finance.yahoo.comArriVent Reports Third-Quarter Results and Oncology Pipeline ProgressNovember 9 at 5:31 PM | tipranks.comArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on MondayNovember 9 at 4:27 AM | americanbankingnews.comSee More ArriVent BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ArriVent BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ArriVent BioPharma and other key companies, straight to your email. Email Address About ArriVent BioPharmaArriVent BioPharma (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations. ArriVent obtained rights to develop and commercialize the drug outside China; its development strategy includes evaluating the treatment in markets beyond its partner’s home territory. Founded in 2021, ArriVent is based in Newtown Square, Pennsylvania. The company’s work centers on advancing its clinical pipeline and supporting the development of targeted cancer therapies.View ArriVent BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
